𝔖 Bobbio Scriptorium
✦   LIBER   ✦

PCN15 PHARMACOECONOMIC ANALYSIS OF EXEMESTANE VERSUS TAMOXIFEN AS ADJUVANT THERAPY FOR PATIENTS WITH EARLY-STAGE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER

✍ Scribed by JM Gil; A Lluch; P González; A Del Castillo; F Canorea; C Rubio-Terrés

Book ID
118607523
Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
81 KB
Volume
8
Category
Article
ISSN
1098-3015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Benefit and projected cost-effectiveness
Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor–positive breast cancer
✍ Bruce E. Hillner 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 1 views

## Abstract ## BACKGROUND Women who have estrogen receptor (ER)‐positive disease with postmenopausal onset and who receive tamoxifen as standard adjuvant treatment constitute the largest subgroup of patients with breast cancer. Recent data from the ATAC (‘Arimidex, Tamoxifen Alone or in Combinatio